Post-Gazette investigators have uncovered how safety advocates within Philips tried to prevent the company from releasing dangerous breathing machines — and were subsequently ignored or silenced by leadership. This new information underscores how lackluster Food and Drug Administration oversight of medical devices has become. But several reforms could reliably protect consumers in the future, including updating the pre-market approval process and properly implementing product tracking.

The stakes are high. Philips recalled about 20 models of ventilator devices in 2021 in one of the largest product recalls in U.S. history. The recalled machines included CPAPs used to treat sleep apnea, a serious condition in which patients stop breathing while asleep. But the sound-dampening foam the company used inside the machines, made of polyester-based polyurethane, or PE-PUR, was breaking down and releasing chemicals into the lungs of users, with devastating effects.

The tragedy was a decade in the making, as Philips attempted to downplay, ignore or minimize growing reports of harm from labs, consumers and its own staff. One Philips engineer grew so distraught at the company’s inaction that she resigned. An internal memo noted that she was spurred by the knowledge that “babies are using our products.”

Now, at least 561 deaths associated with the devices have been reported to the FDA. Thousands of cases of cancer, organ failure and other irreparable health issues have also been reported. It’s clear that the FDA must strengthen its oversight for medical devices to prevent such tragedies in the future.

Advertise with us

Fast-track approval

One of the most obvious regulatory failures was the approval of these harmful devices in the first place.

In the case of Philips, all of their recalled devices received FDA clearance through the 510(k) “fast-track” process, which doesn’t require any clinical testing of a device before it hits the market. This process is meant to lessen the burden for devices that are “substantially equivalent” to an already FDA-approved device.

But, none of the public documents Philips submitted during the 510(k) processes from 2009 to 2013, when the recalled devices were being approved, disclosed the introduction of the PE-PUR foam. This should have been impossible, as the application requires detailed documentation including design drawings and schematics.

The complexity of today’s medical devices make this “fast-track” approval process much higher-stakes. Many of the “industry standard” devices to which new machines must be “substantially equivalent” earned this designation primarily through longevity, not necessarily rigorous testing. As a result, risks can be discovered after the fact, casting doubt on the entire “fast-track” process that’s built on the assumption that “industry standard” devices are safe.

Last September, the FDA proposed reforms to the 510(k) system, one of which would require clinical studies before certain devices receive approval. Basically, a company would have to gather data proving that a new device is just as safe as its predecessor. The guidelines for when this mechanism would apply are all still in draft phases, but Philips should be top-of-mind as regulators consider how small oversight lapses, like failing to take notice of a change to the materials used in noise-dampening foam, can hurt and kill patients.

Advertise with us

Unique Device Identifiers

Philips’ recall effort, long overdue, was also hampered by the fact the company doesn’t track its own devices or the patients who buy them. By the time the recall effort was announced in 2021, 15 million machines were affected globally, but Philips had no idea where they were. The company instead relied on vendors to contact patients — private contractors who have no obligation to keep long-term records or contact information for patients.

This led to a messy and lengthy recall effort, and no way to guarantee that all patients were properly warned. It also led to long wait times for replacement machines, and an overall shortage of the devices. For a condition as serious and life-altering as sleep apnea, making patients choose between the therapy they need and their long-term health is unfair.

This could have easily been prevented through one mechanism: Back in 2013, the FDA implemented a system of unique device identifiers (UDIs) for medical products. These codes help identify a device by its model and production information, like the VIN number on a car. In the event of a recall, patients are able to easily identify their product and find vital information about its manufacturing.

The FDA has already spent years building the infrastructure necessary for the widespread implementation of UDIs. But the ready-made system hasn’t been adopted by health providers and remains in limited use. Ten years into the process, it’s time to make UDIs mandatory across all medical devices.

There is still plenty of work to be done to assess the full scope of Philips’ negligence. But if the FDA can properly improve its 510(k) approval system and fully implement the existing guidelines for UDIs, future disasters the Philips CPAP scandal could be avoided.